ARCUS BIOSCIENCES INC's ticker is RCUS and the CUSIP is 03969F109. A total of 186 filers reported holding ARCUS BIOSCIENCES INC in Q3 2022. The put-call ratio across all filers is 1.07 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $757,759 | -41.9% | 42,215 | -15.4% | 0.00% | -50.0% |
| Q3 2022 | $1,305,000 | -79.9% | 49,891 | -68.9% | 0.00% | -71.4% |
| Q4 2021 | $6,489,000 | +171.8% | 160,336 | +134.3% | 0.01% | +180.0% |
| Q3 2021 | $2,387,000 | -36.9% | 68,445 | -50.3% | 0.01% | -44.4% |
| Q2 2021 | $3,783,000 | +297.8% | 137,752 | +306.7% | 0.01% | +350.0% |
| Q1 2021 | $951,000 | -82.1% | 33,869 | -83.4% | 0.00% | -86.7% |
| Q4 2020 | $5,302,000 | -47.7% | 204,233 | -65.5% | 0.02% | -58.3% |
| Q3 2020 | $10,146,000 | +11.7% | 591,946 | +61.2% | 0.04% | -20.0% |
| Q2 2020 | $9,087,000 | +1106.8% | 367,318 | +576.8% | 0.04% | +650.0% |
| Q1 2020 | $753,000 | -40.3% | 54,271 | -56.6% | 0.01% | +50.0% |
| Q4 2019 | $1,262,000 | +322.1% | 124,973 | +280.4% | 0.00% | +300.0% |
| Q3 2019 | $299,000 | -14.3% | 32,850 | -25.1% | 0.00% | 0.0% |
| Q2 2019 | $349,000 | – | 43,883 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Invus Financial Advisors, LLC | 1,612,077 | $40,850,000 | 24.66% |
| Octagon Capital Advisors LP | 2,669,974 | $67,657,000 | 18.06% |
| Decheng Capital Management III (Cayman), LLC | 869,790 | $22,040,000 | 8.36% |
| BVF INC/IL | 3,960,948 | $100,370,000 | 4.85% |
| Finepoint Capital LP | 535,000 | $13,557,000 | 4.69% |
| PFM Health Sciences, LP | 3,346,458 | $84,799,000 | 3.24% |
| ACUTA CAPITAL PARTNERS, LLC | 167,500 | $4,244,000 | 2.36% |
| Boxer Capital, LLC | 1,432,200 | $36,292,000 | 2.30% |
| Parkman Healthcare Partners LLC | 171,214 | $4,339,000 | 1.60% |
| SECTORAL ASSET MANAGEMENT INC | 311,782 | $7,901,000 | 1.59% |